Clowes Howard 4

What Happened Clowes Howard, a director of Plus Therapeutics (PSTV), received 922 shares on July 1, 2026 through the conversion/vesting of restricted stock units (RSUs). The transaction shows 922 shares acquired at $0.00 (and a corresponding derivative disposition at $0.00), indicating the RSUs converted into common stock with no cash payment.

Key Details

• Transaction date: 2026-07-01
• Reported as derivative exercise/conversion (transaction code M); 922 shares @ $0.00 — total cash exchanged: $0
• Filing does not state total shares owned after the transaction in the provided excerpt
• Footnote F1: Each RSU represents a contingent right to one share of common stock
• Footnote F2: The RSU grant vests in four substantially equal quarterly installments beginning July 1, 2026 (this entry reflects a vesting event)
• No indication in the filing excerpt that this was a sale or part of a 10b5‑1 plan; filing date matches the report date (no late filing noted)

Context The paired "acquired" and "disposed" derivative entries are typical when RSUs vest: the derivative (RSU) is converted/terminated and underlying shares are issued. This was an award/vesting event (not a market purchase or sale), so it is generally a routine compensation-related issuance rather than a directional trading signal.